The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved and that specialty pharmacies and online companies need to stop selling off-brand versions of the weight-loss drugs. The FDA has issued warnings against the off-brand versions, citing safety concerns.

The U.S. Food and Drug Administration said on Thursday there was no longer a shortage of Eli Lilly’s (LLY.N) blockbuster weight loss and diabetes drugs following a re-evaluation of their supply by the agency.

The first medication for obstructive sleep apnea has been approved by the US Food and Drug Administration (FDA).

Following rapid (and pricey) expansion efforts from Novo and Lilly, plus recent shortage updates at the FDA, “positive signals” are emerging when it comes to the consistent supply of GLP-1 medicines for diabetes and weight loss, Bill Coyle, global head of biopharma at ZS, said in a recent interview.

Zepbound, a drug approved by the FDA, has been shown to reduce the severity of obstructive sleep apnea in obese adults, although it is not a cure and requires weight loss to be maintained over time.

In a recent head-to-head study involving Novo Nordisk 's Wegovy, Zepbound came out on top, resulting in average weight loss of about 20%, compared to more than 13% for the rival medicine. Lilly and Novo Nordisk both are leaders in this market today.

Eli Lilly (LLY) announced today that its blockbuster weight-loss drug Zepbound was approved by the U.S. Food and Drug Administration (FDA) as the first prescription drug to help alleviate moderate-to-severe obstructive sleep apnea (OSA) for adults with obesity.

The FDA has expanded the approval of Eli Lilly’s obesity medication Zepbound to include treating moderate to severe obstructive sleep apnea for people with obesity.

The FDA has doubled down on its decision to remove Eli Lilly’s tirzepatide from its list of products that are in shortage. | The FDA has doubled down on its decision to remove Eli Lilly’s tirzepatide from its list of products that are in shortage.

The FDA said Thursday it’s standing by its earlier decision that the shortage of tirzepatide — the active ingredient in Eli Lilly’s diabetes and weight loss drugs Mounjaro and Zepbound — is over.

Investing in rapidly expanding biotech stocks can be a worthwhile long-term investment. Just one successful drug or device can propel a biotech company to new heights. And biotech companies that use cutting-edge technology or treat complex diseases will always be in demand.

The Food and Drug Administration on Friday approved Eli Lilly’s weight-loss drug Zepbound to treat sleep apnea, a common but potentially serious sleep-related breathing disorder, marking it the first medication for certain patients with the condition.